🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

5,609 results for “AB” Clear

  1. Carboplatin Hikma 10 mg/ml Konzentrat zur Herstellung einer Infusionslösung, CARBO-cell® 10 mg/ml Infusionslösung, Konzentrat zur Herstellung einer Infusionslösung, JNJ-61186372, Carboplatin Kabi 10 mg/ml Konzentrat zur Herstellung einer Infusionslösung, KEYTRUDA 25 mg/mL concentrate for solution for infusion., KEYTRUDA 25 mg/mL concentrate for solution for infusion

    Janssen-Cilag International N.V.

    Head and Neck Squamous Cell Carcinoma

    phase 2 small molecule active

    1 trial

  2. Carboplatin Hikma 10 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Pemetrexed Accord 25 mg/ml concentrate for solution for infusion, Paclitaxel Bendalis 6 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Mycofit, 250 mg, kapsułki twarde, Remsima 100 mg powder for concentrate for solution for infusion, volrustomig, Cyramza 10 mg/ml concentrate for solution for infusion

    AstraZeneca AB

    Solid Tumors, SQ, NSQ NSCLC

    phase 2 small molecule active

    1 trial

  3. Carboplatin Kabi 10 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Cisplatin Hikma 1 mg/ml Konzentrat zur Herstellung einer Infusionslösung, CARBO-cell® 10 mg/ml Infusionslösung, Konzentrat zur Herstellung einer Infusionslösung, Alectinib (Alecensa), Pemetrexed Fresenius Kabi 25 mg/ml concentrate for solution for infusion, Cisplatin NeoCorp 1 mg/ml - Konzentrat zur Herstellung einer Infusionslösung, Pemetrexed Accord 25 mg/ml concentrate for solution for infusion, Pemetrexed Pfizer 25 mg/ml concent

    Hoffmann-La Roche

    Resectable Stage I-III Non-Small Cell Lung Cancer (NSCLC)

    phase 2 small molecule active

    1 trial

  4. Cemiplimab

    Regeneron UK Limited

    Colo-rectal Cancer

    phase 2 small molecule active

    1 trial

  5. Cemiplimab

    Regeneron UK Limited

    Head and Neck Squamous Cell Carcinoma

    phase 2 small molecule active

    1 trial

  6. Cemiplimab

    Regeneron UK Limited

    Colon Cancer

    phase 2 small molecule active

    1 trial

  7. Cemiplimab

    Regeneron UK Limited

    Colon and Rectal Cancer

    phase 2 small molecule active

    1 trial

  8. Cemiplimab

    Regeneron UK Limited

    Metastatic Solid Tumor

    phase 2 small molecule active

    1 trial

  9. Cemiplimab

    Regeneron UK Limited

    HPV-Related Squamous Cell Carcinoma

    phase 2 small molecule active

    1 trial

  10. Cemiplimab

    Regeneron UK Limited

    Lung Cancer (NSCLC)

    phase 2 small molecule active

    1 trial

  11. Cemiplimab

    Regeneron UK Limited

    Basal Cell Carcinoma (BCC)

    phase 2 small molecule active

    1 trial

  12. Cemiplimab

    Regeneron UK Limited

    High-Grade Glioma (HGG)

    phase 2 small molecule active

    1 trial

  13. Cemiplimab

    Regeneron UK Limited

    Locally Recurrent Oral Cavity Squamous Cell Carcinoma

    phase 2 small molecule active

    1 trial

  14. Cemiplimab

    Regeneron UK Limited

    NSCLC

    phase 2 small molecule active

    1 trial

  15. Cemiplimab

    Regeneron UK Limited

    Colorectal Cancer

    phase 2 small molecule active

    1 trial

  16. Cemiplimab

    Regeneron UK Limited

    Carcinoma, Non-Small-Cell Lung

    phase 2 small molecule active

    1 trial

  17. Cemiplimab

    Regeneron UK Limited

    Hodgkin Lymphoma

    phase 2 small molecule terminated

    1 trial

  18. Cemiplimab

    Regeneron UK Limited

    Locally Advanced Basal Cell Carcinoma

    phase 2 mab active

    1 trial

  19. Cemiplimab

    Regeneron UK Limited

    Bladder Urothelial Carcinoma

    phase 2 small molecule active

    1 trial

  20. Cemiplimab

    Regeneron UK Limited

    Hepatitis B Virus

    phase 2 mab terminated

    1 trial

  21. Cemiplimab

    Regeneron UK Limited

    Pleural Mesotheliomas

    phase 2 small molecule active

    1 trial

  22. Cemiplimab

    Regeneron UK Limited

    Cervical Cancer

    phase 2 small molecule completed

    1 trial

  23. Cemiplimab

    Regeneron UK Limited

    HIV Infections

    phase 2 mab terminated

    1 trial

  24. Cemiplimab + Fianlimab [Fixed Dose Combination (FDC)]

    Regeneron UK Limited

    Colon Cancer

    phase 2 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources